Harbor BioMed Announces Upcoming Poster Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

CAMBRIDGE, Mass., ROTTERDAM, The Netherlands and SUZHOU, China, October 13, 2022 /PRNewswire/ — Harbor BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical company engaged in the discovery, development and commercialization of novel antibody therapeutics focused on oncology and immunology, announced today Today the Company will showcase new data from five portfolio assets, including HBM7008, HBM7004, HBM1047, HBM1020 and HBM1022 in five poster presentations at 37e Annual meeting of the Society for Immunotherapy of Cancer (SITC) in Bostonvia in-person/virtual presence, November 8-12, 2022.

List of poster presentations:

Title: HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in a preclinical model
Abstract number: 477

Title: HBM7008 (B7H4x4-1BB HBICE) synergizes HBM7004 (B7H4xCD3 HBICE) for the treatment of solid tumors
Abstract number: 858

Title: HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4-1BB, exhibits robust antitumor immunity and low toxicity through B7-H4-directed activation of 4-1BB
Abstract number: 1057

Title: HBM1020 is a novel fully human anti-B7H7 antibody with excellent preclinical efficacy and an excellent safety profile
Abstract number: 1075

Title: HBM1022: an afucosylated anti-CCR8 antibody specifically depletes tumor infiltrating Tregs and inhibits tumor growth with an excellent safety profile in preclinical studies
Abstract number: 1361

More details on the SITC annual meeting are available on the official site. The full text of the abstracts will be made public on November 7, 2022, 8:00 a.m. EST. All posters will be presented on Thursday, November 10-11, 2022of 9:00 a.m. to 9:00 p.m. ESTat the Boston Convention & Exhibition Center, Exhibit Hall C.

About Harbor BioMed

Harbor BioMed (HKEX: 02142) is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel antibody therapeutics focused on immunology and oncology. The company is building its strong portfolio and differentiated pipeline through in-house R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The Company’s proprietary antibody technology platforms, Harbor Mice®, generate fully human monoclonal antibodies in both heavy chain and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Based on HCAb antibodies, HCAb-based Immune Cell Activators (HBICE®) are capable of producing tumor-killing effects unachievable by traditional combination therapies. Integrating Harbor Mice®, HBICE® with a unique B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies.

SOURCE Port BioMed

Comments are closed.